Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2012
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
Hedy L Kindler, Theodore G Karrison, David R Gandara, et al.
European Urology Oncology
|
July 13, 2023
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M Dahl, Theodore G Karrison, M Dror Michaelson, et al.
Blood Advances
|
July 28, 2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
Kirk E Cahill, James K Godfrey, Chadi Nabhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer
Ezra E W Cohen, Theodore G Karrison, Masha Kocherginsky, et al.
European Urology
|
June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
European Urology
|
May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2018
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Jason J Luke, Jeffrey M Lemons, Theodore G Karrison, et al.
Journal of Clinical Bioinformatics
|
May 24, 2011
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database
Mosmi Surati, Matthew Robinson, Suvobroto Nandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2014
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib
Michael L Maitland, Chun-Fang Xu, Yu-Ching Cheng, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2012
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
Hedy L Kindler, Theodore G Karrison, David R Gandara, et al.
European Urology Oncology
|
July 13, 2023
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
Douglas M Dahl, Theodore G Karrison, M Dror Michaelson, et al.
Blood Advances
|
July 28, 2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL
Kirk E Cahill, James K Godfrey, Chadi Nabhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2014
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer
Ezra E W Cohen, Theodore G Karrison, Masha Kocherginsky, et al.
European Urology
|
June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
European Urology
|
May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2018
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Jason J Luke, Jeffrey M Lemons, Theodore G Karrison, et al.
Journal of Clinical Bioinformatics
|
May 24, 2011
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database
Mosmi Surati, Matthew Robinson, Suvobroto Nandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2014
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib
Michael L Maitland, Chun-Fang Xu, Yu-Ching Cheng, et al.
Page
of 7